Literature DB >> 24149063

Cardiac Resynchronization Therapy MOdular REgistry: ECG and Rx predictors of response to cardiac resynchronization therapy (NCT01573091).

Giuseppe Stabile1, Emanuele Bertaglia, Gianluca Botto, Francesco Isola, Giosuè Mascioli, Patrizia Pepi, Salvatore I Caico, Antonio De Simone, Antonio D'Onofrio, Domenico Pecora, Pietro Palmisano, Giampiero Maglia, Giuseppe Arena, Maurizio Malacrida, Luigi Padeletti.   

Abstract

AIMS: A variable proportion, up to 30%, of patients who undergo cardiac resynchronization therapy (CRT) do not benefit from treatment. The aim of the Cardiac Resynchronization Therapy MOdular REgistry (CRT MORE) is to determine whether specific electrocardiographic and radiographic parameters can be used to predict clinical and echocardiographic response to CRT.
METHODS: The CRT MORE is a prospective, single-arm, multicenter cohort study designed to evaluate the electrocardiographic and radiographic predictors of response to CRT. All study patients receive a pacemaker or implantable defibrillator for CRT delivery in accordance with current guidelines. Enrollment started in December 2011 and is scheduled to end in November 2013. Approximately 1100 consecutive patients will be enrolled in 30 Italian centers and will be followed up for 60 months after implantation. The primary endpoint is the improvement in clinical (Clinical Composite Score) and echocardiographic (a decrease of ≥ 15% in left ventricular end-systolic volume) parameters at the 6-month follow-up visit.
CONCLUSION: This study might provide important information about which electrocardiographic and radiographic parameters better predict CRT response.

Entities:  

Mesh:

Year:  2013        PMID: 24149063     DOI: 10.2459/JCM.0b013e3283644bb2

Source DB:  PubMed          Journal:  J Cardiovasc Med (Hagerstown)        ISSN: 1558-2027            Impact factor:   2.160


  3 in total

1.  Incidence, predictors, and impact on outcome of increased left ventricular latency in patients undergoing cardiac resynchronization therapy.

Authors:  Antonio D'Onofrio; Salvatore Ivan Caico; Assunta Iuliano; Paolo Pieragnoli; Valter Bianchi; Daniela Orsida; Antonio Pani; Mario Pasqualini; Francesca Amadori; Ludovico Vasquez; Antonello Talarico; Chiara Minoia; Roberto Ospizio; Greta Merlotti; Maurizio Malacrida; Giuseppe Stabile
Journal:  J Interv Card Electrophysiol       Date:  2018-03-03       Impact factor: 1.900

2.  Prognostic Role of Right Ventricular Function in Patients With Heart Failure Undergoing Cardiac Resynchronization Therapy.

Authors:  Antonio Rapacciuolo; Stefano Maffè; Pietro Palmisano; Anna Ferraro; Antonella Cecchetto; Antonio D'Onofrio; Francesco Solimene; Paola Musatti; Paola Paffoni; Francesca Esposito; Umberto Parravicini; Alessia Agresta; Giovanni Luca Botto; Maurizio Malacrida; Giuseppe Stabile
Journal:  Clin Cardiol       Date:  2016-07-28       Impact factor: 2.882

3.  The VALID-CRT risk score reliably predicts response and outcome of cardiac resynchronization therapy in a real-world population.

Authors:  Emanuele Bertaglia; Giuseppe Arena; Domenico Pecora; Albino Reggiani; Antonio D'Onofrio; Pietro Palmisano; Antonio De Simone; Salvatore I Caico; Massimiliano Marini; Giampiero Maglia; Anna Ferraro; Francesco Solimene; Antonella Cecchetto; Maurizio Malacrida; Giovanni L Botto; Maurizio Lunati; Giuseppe Stabile
Journal:  Clin Cardiol       Date:  2019-07-13       Impact factor: 2.882

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.